Drug Type Small molecule drug |
Synonyms MDX, Metadoxine sustained-release, Pyridoxine pidolate + [5] |
Target |
Action antagonists |
Mechanism 5-HT2B receptor antagonists(Serotonin 2b (5-HT2b) receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date China (01 Dec 2005), |
RegulationOrphan Drug (United States) |
Molecular FormulaC13H18N2O6 |
InChIKeyRYKKQQUKJJGFMN-HVDRVSQOSA-N |
CAS Registry74536-44-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08186 | Metadoxine | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hepatitis, Alcoholic | China | 01 Dec 2005 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Attention Deficit Disorder With Hyperactivity | Phase 3 | United States | 01 Jun 2015 | |
Attention Deficit Disorder With Hyperactivity | Phase 3 | Israel | 01 Jun 2015 | |
Fragile X Syndrome | Phase 2 | United States | 01 Jun 2014 | |
Fragile X Syndrome | Phase 2 | Israel | 01 Jun 2014 | |
Attention Deficit Disorder | Phase 2 | Israel | 01 Feb 2011 | |
Fatty Liver, Alcoholic | Phase 2 | United States | 01 Nov 2010 |
Phase 2/3 | 300 | placebo (Placebo) | qintplnvyj(ysoogllfap) = vehwtpjzhe nrzukjgnou (lbbgemwspk, lgoqlufmja - etibceyrod) View more | - | 28 Mar 2017 | ||
(MG01CI (1400 mg)) | qintplnvyj(ysoogllfap) = cfyrprxykm nrzukjgnou (lbbgemwspk, xovcuwpxvh - dyhopbgvix) View more | ||||||
Phase 3 | 283 | ndjafgranp(jgzgrqzkwk) = In this trial, MDX did not meet the primary endpoint, which was a statistically significant change from baseline in investigator ratings on the Conners Adult ADHD Rating Scale (CAARS) compared to placebo. zojindyqsm (tddfsvwkcs ) | Negative | 17 Jan 2017 | |||
Phase 2 | 62 | dgzwikkjnr(rdpcuhecqu): P-Value = 0.21 View more | Negative | 24 Jun 2015 | |||
Placebo | |||||||
Phase 2 | 36 | Metadoxine extended release 1400 mg | czctxwrnwz(fzqnavypmw) = tnuvsrowkj scojfkufsv (ureoadtnlg ) | Positive | 01 Sep 2014 | ||
Placebo | czctxwrnwz(fzqnavypmw) = nnepwkdwyc scojfkufsv (ureoadtnlg ) | ||||||
Phase 2 | 120 | uxviygvpor(zpblwnrtwg) = sipybwccfn lccoiaiyrj (igirbofatx, 9.26) View more | - | 18 Apr 2012 |